Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares for approximately $4.91 million at an average price of $517.28, reducing her stake by 2.84% to 324,443 shares.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analysts maintain a “Moderate Buy” consensus, with 11 Buy ratings and two Holds and an average price target of $646; institutional investors own 94.08% of the stock.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $517.28, for a total value of $4,914,160.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at $167,827,875.04. The trade was a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
United Therapeutics Stock Up 2.2%
UTHR opened at $527.91 on Friday. The stock's fifty day moving average is $530.89 and its two-hundred day moving average is $538.86. The company has a market capitalization of $22.64 billion, a P/E ratio of 18.89, a PEG ratio of 1.75 and a beta of 0.59. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. During the same period in the prior year, the business earned $6.41 EPS. The business's revenue for the quarter was down 1.9% compared to the same quarter last year. Equities analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.
Institutional Trading of United Therapeutics
A number of institutional investors have recently modified their holdings of UTHR. Torren Management LLC purchased a new position in shares of United Therapeutics in the 4th quarter worth approximately $26,000. Toth Financial Advisory Corp lifted its position in United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 48 shares during the last quarter. Activest Wealth Management lifted its position in United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Fiduciary Financial Advisors acquired a new stake in United Therapeutics in the second quarter valued at approximately $30,000. Finally, WealthCollab LLC boosted its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on UTHR. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. TD Cowen reaffirmed a "buy" rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $515.00 price objective on shares of United Therapeutics in a research note on Thursday, August 6th. Royal Bank Of Canada lowered their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a report on Thursday, August 6th. Finally, Bank of America dropped their target price on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $646.00.
Read Our Latest Stock Analysis on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
